FLOVENT DISKUS Rx
Generic Name and Formulations:
Fluticasone propionate 50mcg/inh, 100mcg/inh, 250mcg/inh; dry pwd for inhalation; blisters with inhalation device.
Indications for FLOVENT DISKUS:
Maintenance treatment of asthma as prophylactic therapy.
Limitations Of use:
Not for the relief of acute bronchospasm.
Previously on bronchodilators alone: initially 100mcg twice daily (approx. 12hrs apart); max 1000mcg twice daily. Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
<4yrs: not established. 4–11yrs: Previously on bronchodilators alone: initially 50mcg twice daily (approx. 12hrs apart); max 100mcg twice daily. Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
Primary treatment of status asthmaticus or other acute attacks requiring intensive measures. Severe milk protein hypersensitivity.
Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Change in vision or history of increased intraocular pressure, glaucoma, and/or cataracts; monitor. Monitor for reduction in bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occur discontinue gradually). Eosinophilic conditions. Hepatic impairment (monitor). Transferring from oral corticosteroids: see full labeling. Pregnancy. Nursing mothers.
Concomitant strong CYP3A4 inhibitors (eg, ritonavir, ketoconazole): not recommended.
Upper respiratory tract infection/inflammation, throat irritation, sinusitis, rhinitis, oral candidiasis, nausea, vomiting, GI discomfort, fever, cough, bronchitis, headache; immunosuppression, adrenal suppression, bronchospasm, hypersensitivity reactions.
Diskus (60 blisters)—1
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|